MEL60 - Immunotherapy study for patients with stage IIB-IV melanoma

IRB/UVA Tracking #
15931
Principal Investigator
Slingluff Craig, L
Contact First Name

Emily

Contact Last Name

Allred

Contact Email
Contact Phone
Official Trial Title
PHASE I/II TRIAL OF A LONG PEPTIDE VACCINE (LPV7) PLUS TLR AGONISTS FOR RESECTED STAGE IIB – IV MELANOMA
Study Description

The University of Virginia Cancer Center Human Immune Therapy Center seeks men and women age 18 years and older with Stage IIB-IV melanoma for a cancer vaccine study. Cancer vaccines are medicines that work by stimulating or restoring the immune system’s ability to fight infections and disease.

To be eligible, participants must be clinically free of disease at this time.

The purpose of this study is to evaluate the safety of an experimental vaccine plus immune system stimulants in patients with melanoma. Researchers are looking to determine how the immune system responds to these combinations.
Participants will receive the experimental vaccine and be randomized (like with a flip of a coin) to also receive different immune system stimulants. If eligible, participants will be in the study for about 2 years.
There is no compensation for participating in this study. Investigational products are provided free of charge.

For more information, or to see if you qualify to take part in this study, please contact:

Contact: Emily Allred
Phone: (434)924-2293
Email: eh4m@virginia.edu

Primary Investigator: Craig Slingluff, MD
IRB-HSR# 15931

Compensation

No Compensation